Radiation Oncology (May 2022)

Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)

  • Sebastian Regnery,
  • Jonas Ristau,
  • Fabian Weykamp,
  • Philipp Hoegen,
  • Simon David Sprengel,
  • Katharina Maria Paul,
  • Carolin Buchele,
  • Sebastian Klüter,
  • Carolin Rippke,
  • Claudia Katharina Renkamp,
  • Moritz Pohl,
  • Jan Meis,
  • Thomas Welzel,
  • Sebastian Adeberg,
  • Stefan Alexander Koerber,
  • Jürgen Debus,
  • Juliane Hörner-Rieber

DOI
https://doi.org/10.1186/s13014-022-02070-x
Journal volume & issue
Vol. 17, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Stereotactic Body Radiotherapy (SBRT) is a standard treatment for inoperable primary and secondary lung tumors. In case of ultracentral tumor location, defined as tumor contact with vulnerable mediastinal structures such as the proximal bronchial tree (PBT) or esophagus, SBRT is associated with an increased risk for severe complications. Magnetic resonance (MR)-guided SBRT can mitigate this risk based on gated dose delivery and daily plan adaptation. The MAGELLAN trial aims to find the maximum tolerated dose (MTD) of MR-guided SBRT of ultracentral lung tumors (ULT). Patients and methods MAGELLAN is a prospective phase I dose escalation trial. A maximum of 38 patients with primary and secondary ULT with a tumor size ≤ 5 cm will be enrolled. Ultracentral location is defined as an overlap of the planning target volume (PTV) with the PBT or esophagus. Patients are treated at a 0.35 Tesla MR-linac (MRIdian® Linac, ViewRay Inc. ) employing a gating strategy and daily plan adaptation. Dose escalation starts at 10 × 5.5 Gy (biologically effective dose BED3/10: 155.83 Gy/85.25 Gy), may proceed up to 10 × 6.5 Gy (BED3/10: 205.83 Gy/107.25 Gy) and is guided by a customized time-to-event continual reassessment method (TITE CRM) with backup element, which alternately assigns patients to dose escalation and backup cohorts. Discussion The results of the MAGELLAN trial will guide further research and clinical implementation of MR-guided SBRT as ablative treatment of ULT. Moreover, the combination of MR-guided radiotherapy with TITE-CRM including a backup element may serve as blueprint for future radiation dose escalation studies in critical locations. Trial Registration Registered at ClinicalTrials.gov: NCT04925583 on 14th June 2021.

Keywords